Interferon-inducer antivirals: Potential candidates to combat COVID-19

 Ashkan Bagheri a,b,c,d,1 , Seyed Mohammad Iman Moezzi a,b,c,d,1 , Pouria Mosaddeghi a,b,c,d , Sadra Nadimi Parashkouhi a,b,c,d , Seyed Mostafa Fazel Hoseini a,b,c,d , Fatemeh Badakhshan a,b,c,d , Manica Negahdaripour a,b,*

ABSTRACT 

Coronavirus disease 2019 (COVID-19) is an infective disease generated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given the pandemic urgency and lack of an effective cure for this disease, drug repurposing could open the way for finding a solution. Lots of investigations are ongoing to test the compounds already identified as antivirals. On the other hand, induction of type I interferons are found to play an important role in the generation of immune responses against SARS-CoV-2. Therefore, it was opined that the antivirals capable of triggering the interferons and their signaling pathway, could rationally be beneficial for treating COVID-19. On this basis, using a database of antivirals, called drugvirus, some antiviral agents were derived, followed by searches on their relevance to interferon induction. The examined list included drugs from different categories such as antibiotics, immunosuppressants, anti-cancers, non-steroidal anti-inflammatory drugs (NSAID), calcium channel blocker compounds, and some others. The results as briefed here, could help in finding potential drug candidates for COVID-19 treatment. However, their advantages and risks should be taken into account through precise studies, considering a systemic approach. Even though the adverse effects of some of these drugs may overweight their benefits, considering their mechanisms and structures may give a clue for designing novel drugs in the future. Furthermore, the antiviral effect and IFN-modifying mechanisms possessed by some of these drugs might lead to a synergistic effect against SARS-CoV-2, which deserve to be evaluated in further investigations. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705326/pdf/main.pdf